Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors

CellRank for directed single-cell fate mapping

(2022) Marius Lange et al.   NATURE METHODS

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity

(2022) Takumi Maruhashi et al.   IMMUNITY

Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer

(2022) Maxime Meylan et al.   IMMUNITY

Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome

(2022) Elisa Ciraolo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation

(2022) Clifford Guy et al.   NATURE IMMUNOLOGY

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

(2022) Alexander C. Huang et al.   NATURE IMMUNOLOGY

NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity

(2022) Nicole Kirchhammer et al.   Science Translational Medicine

A human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1

(2021) Fabian Junker et al.   CYTOMETRY PART A

Inference and analysis of cell-cell communication using CellChat

(2021) Suoqin Jin et al.   Nature Communications

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

(2021) Miguel F Sanmamed et al.   Cancer Discovery

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake

(2021) Álvaro de Mingo Pulido et al.   IMMUNITY

Cytokine-skewed Tfh cells: functional consequences for B cell help

(2021) Adesola C. Olatunde et al.   TRENDS IN IMMUNOLOGY

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies

(2021) Marta Trüb et al.   Frontiers in Immunology

Integrated analysis of multimodal single-cell data

(2021) Yuhan Hao et al.   CELL

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

(2021) Karen O. Dixon et al.   NATURE

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

(2021) Paula Voabil et al.   NATURE MEDICINE

Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy

(2021) Julie Niogret et al.   Journal for ImmunoTherapy of Cancer

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

(2021) Yuanyuan Zhang et al.   CANCER CELL

Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses

(2021) Can Cui et al.   CELL

Peripheral T cell expansion predicts tumour infiltration and clinical response

(2020) Thomas D. Wu et al.   NATURE

Acquired Resistance to Immune Checkpoint Inhibitors

(2020) Adam J. Schoenfeld et al.   CANCER CELL

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

(2020) Matthew Kraman et al.   CLINICAL CANCER RESEARCH

Generalizing RNA velocity to transient cell states through dynamical modeling

(2020) Volker Bergen et al.   NATURE BIOTECHNOLOGY

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

(2020) Floris Dammeijer et al.   CANCER CELL

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

(2020) Natalia Rodrigues Mantuano et al.   Journal for ImmunoTherapy of Cancer

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

(2019) Sema Kurtulus et al.   IMMUNITY

A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer

(2019) Hagma H Workel et al.   Cancer Immunology Research

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

BBKNN: fast batch alignment of single cell transcriptomes

(2019) Krzysztof Polański et al.   BIOINFORMATICS

Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia

(2018) Marina Wierz et al.   BLOOD

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

(2018) Flávia Castro et al.   Frontiers in Immunology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice

(2018) Adeline Crinier et al.   IMMUNITY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

(2016) Marie-Caroline Dieu-Nosjean et al.   IMMUNOLOGICAL REVIEWS

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

(2016) Tilman Schlothauer et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

(2016) Ruea-Yea Huang et al.   OncoImmunology

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

(2016) Gulidanna Shayan et al.   OncoImmunology

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

(2014) Erika Assarsson et al.   PLoS One

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

(2014) Charity W Law et al.   GENOME BIOLOGY

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Proinflammatory T helper type 17 cells are effective B-cell helpers

(2010) M. Mitsdoerffer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA